MSPharma
MS Pharma is a privately held Jordan-headquartered multinational pharmaceutical company that develops, manufactures, and distributes generic, specialty, and biologic medicines across the MENA region through five production facilities in Jordan, Algeria, and Saudi Arabia, serving healthcare providers, government health systems, and global pharma partners in 70+ countries.
- Company typePrivate
- Founded2011
- HeadquartersAmman, Jordan
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What MSPharma does
MS Pharma is a privately held, Jordan-headquartered multinational pharmaceutical group that develops, manufactures, and commercializes generic and specialty medicines across the Middle East and North Africa (MENA). The group operates five manufacturing facilities across Jordan (United Pharmaceuticals/UPM for non-sterile oral solids and cephalosporins; MS Pharma Injectables/MSPI for sterile injectables), Algeria (El Kendi, the country's largest pharmaceutical production facility with a new oncological unit added in 2025), and Saudi Arabia (an oral solids site plus the newly inaugurated MENA-first biologics manufacturing hub in Riyadh), producing a portfolio of 300 INNs spanning cardiovascular, central nervous system, respiratory, and oncology therapeutic areas in solids, liquids, cytotoxics, and sterile injectable dosage forms.
The company's revenue model rests on three pillars: direct sales of generics and specialty pharmaceuticals through its own sales and marketing offices in 10+ MENA countries (Algeria, Jordan, Saudi Arabia, UAE, Kuwait, Oman, Bahrain, Qatar, Iraq) with distribution to 70+ countries; exclusive licensing, supply, and commercialization agreements with global pharmaceutical innovators seeking MENA market access (notably Formycon AG for the FYB206 pembrolizumab biosimilar); and contract manufacturing of biologics and complex peptides at its EMA/FDA-aligned Riyadh facility — the first site in the Kingdom to receive SFDA BPF approval for biological product manufacturing and the first in MENA to operate in-house bioanalytical testing laboratories. Products are procured via tenders, institutional buyers, and government health systems rather than published list prices.
Customer segments span healthcare providers and patients across MENA (primary segment), global pharmaceutical companies seeking GMP-certified MENA/EU/US market entry through licensing or contract manufacturing, and biopharmaceutical innovators/biosimilar developers requiring regional commercialization partners. The Sukhtian family retains board control (four of seven directors), while executive leadership is run from a Corporate Management Office (MS Pharma International AG) in Zug, Switzerland, led by CEO Kalle Känd. In May 2026, Olayan Financing Company took a strategic minority equity stake to support further biosimilar and manufacturing expansion aligned with Saudi Vision 2030.
MSPharma firmographics
Firmographics- Name
- MSPharma
- Legal name
- MS Pharma International AG
- Website
- https://mspharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- MS Pharma is a privately held Jordan-headquartered multinational pharmaceutical company that develops, manufactures, and distributes generic, specialty, and biologic medicines across the MENA region through five production facilities in Jordan, Algeria, and Saudi Arabia, serving healthcare providers, government health systems, and global pharma partners in 70+ countries.
- Ownership category
- akta.pro rank
MSPharma industry classification
Industry- Product category
- Generic Pharmaceuticals Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where MSPharma is headquartered
LocationHeadquarters
- HQ city
- Amman
- HQ country
- Jordan
- HQ region
- Middle East
Markets served
MSPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic and Specialty Pharmaceutical Sales: Primary revenue stream from sales of generic and specialty medicines across 70+ countries, with a diversified product portfolio spanning cardiovascular, central nervous system, respiratory, oncology, and other therapeutic areas in solid, liquid, cytotoxic, and sterile injectable dosage forms.
- Licensing, Supply, and Commercialization Partnerships: Revenue from exclusive licensing, supply, and commercialization agreements with global pharmaceutical companies seeking access to MENA markets (e.g., exclusive commercialization of Formycon's FYB206 / Keytruda biosimilar for the MENA region). Includes potential future expansion and technology transfer.
- Biosimilars and Biologics Portfolio Revenue: Revenue stream from biosimilars (e.g., FYB206 pembrolizumab biosimilar) and locally manufactured biologics (monoclonal antibodies, complex peptides) in Saudi Arabia, leveraging first-mover position as the first provider of locally manufactured biologics in the Saudi market.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
MSPharma product offering
Product offeringCore offering
MS Pharma is a multinational pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines, including biosimilars and biologics, across the MENA region and 70+ countries worldwide. Operating five production facilities in Jordan, Algeria, and Saudi Arabia, the company holds 2,000+ marketing authorizations across 300 INNs spanning cardiovascular, CNS, respiratory, and oncology therapeutic areas. It also serves as a strategic manufacturing and partnership platform for global pharmaceutical companies seeking MENA, EU, and US market access through licensing, supply, and commercialization agreements.
Product overview
MS Pharma operates a platform-plus-subsidiaries product architecture centered on a single diversified pharmaceutical offering — generic and specialty medicines plus a growing biologics/biosimilars platform — delivered through multiple coordinated manufacturing and commercial brands. The Generic Pharmaceuticals Portfolio (active in cardiovascular, CNS, respiratory, and oncology) is produced across subsidiaries including United Pharmaceuticals (UPM) for non-sterile oral and cephalosporin manufacturing in Jordan, MS Pharma Injectables (MSPI) for sterile injectables in Jordan, and El Kendi in Algeria for solid dose, liquid, cream, and (since 2025) oncology products. Layered on top is the Biologics and Biosimilars Portfolio, anchored by MS Pharma's newly inaugurated Riyadh biologics hub (monoclonal antibodies, peptides, fill/finish) and including the in-licensed FYB206 pembrolizumab biosimilar partnered with Formycon for the MENA region. Together with Specialty Medicines, these form a unified pharma product portfolio marketed in 70+ countries under a single MS Pharma brand.
Differentiator
Problem solved
Functional benefit
Brands
- El Kendi: Algerian generic pharmaceutical subsidiary brand; the leading generic pharmaceutical company in Algeria with more than 75 INNs on the market.
- UPM (United Pharmaceuticals)
- MSPI (MS Pharma Injectables)
Products and services
- Generic Pharmaceuticals Portfolio A wide range of generic medicines marketed across multiple therapeutic areas including cardiovascular, central nervous system, respiratory, and oncology, with dosage forms spanning solids, liquids, cytotoxic drugs, and sterile injectables. Backed by 2,000+ marketing authorisations and 300 INNs/molecules, produced across subsidiaries in Jordan, Algeria, and Saudi Arabia.
- Biologics and Biosimilars Portfolio Biotech and biosimilar product line manufactured at MS Pharma's new Riyadh biologics facility, with capabilities for monoclonal antibodies, complex peptides, liquid vials, freeze-dried vials, cartridges, and prefilled syringes/pens. Designed to EMA and FDA standards with SFDA GMP approval.
- FYB206 (pembrolizumab biosimilar) Biosimilar candidate to Keytruda (pembrolizumab) for oncology, in-licensed from Formycon AG under an exclusive licensing and supply agreement for the MENA region, with potential for future expansion and technology transfer.
- Specialty Medicines Specialty pharmaceutical products including cytotoxic drugs and complex sterile injectables in therapeutic areas such as oncology, serving MENA, GCC, and African markets through the MSPI (MS Pharma Injectables) subsidiary in Jordan. The MSPI portfolio spans hematology, CNS, systemic anti-infectives, musculoskeletal, GI tract, and oncology with more than 100 products.
- Oncology Treatments (Algeria manufacturing unit) In 2025, a new dedicated manufacturing unit for oncological treatments was added to the El Kendi site in Algeria, expanding the local availability of cancer therapies and MS Pharma's specialized pharmaceutical production capabilities.
Quantifiable outcome
- First provider of locally manufactured biologics in Saudi Arabia through SFDA BPF-approved facility
- +4 more outcomes
Companies that use MSPharma
Customer profileSegments3 records
Ideal customer profiles3 records
MSPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MSPharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Formycon AGcoreFormycon AG and MS Pharma entered into an exclusive licensing and supply agreement for the commercialization of FYB206, a biosimilar candidate to Keytruda® (pembrolizumab), in the Middle East and North Africa (MENA). The collaboration aims to increase access to this cancer drug across the region, with potential for future expansion and technology transfer. FYB206 is Formycon's pembrolizumab biosimilar candidate.
Scale indicators13 records
Recent moves8 records
Expansion highlights7 records
MSPharma competitors and assessment
Company assessmentDirect peers
- Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company focused on generics, injectables, and branded products across MENA and the US. Most directly comparable to MS Pharma by geography, product mix (generics + injectables), and MENA leadership ambitions.
- Tabuk Pharmaceuticals: Saudi Arabia-based generics and specialty pharmaceutical manufacturer with a leading position in the Kingdom and MENA expansion. Comparable to MS Pharma Saudi's product portfolio and Kingdom-market focus.
- Julphar (Gulf Pharmaceutical Industries): UAE-based regional pharmaceutical manufacturer producing generics, specialty, and biotech products across MENA. Comparable to MS Pharma in regional manufacturing footprint, product breadth, and GCC sales presence.
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-headquartered pharmaceutical manufacturer producing generics and specialty products for the Kingdom and MENA. Direct comparable to MS Pharma Saudi in KSA generic and specialty manufacturing.
Broad incumbents
- Cipla: India-headquartered global pharmaceutical company with a strong MENA presence across generics, specialty, and increasingly biosimilars. Comparable in generic product breadth and emerging-market commercialisation model.
- Aurobindo Pharma: India-based global generic and specialty pharmaceutical manufacturer with growing MENA and biosimilar footprints. Comparable in generics-led revenue model and emerging-market distribution intensity.
- Sandoz (Novartis): Global leader in generics and biosimilars, including MAb biosimilars. Comparable in biosimilar product category and the FYB206/pembrolizumab biosimilar competitive set MS Pharma is targeting in MENA.
Regional players
- EIPICO (Egyptian International Pharmaceutical Industries Co.): Egypt-headquartered generic pharmaceutical manufacturer with regional MENA reach. Comparable in Arab-market generics positioning, though with primary geographic focus on Egypt rather than Levant/GCC.
Emerging players
- Acino International: Switzerland-headquartered specialty and generics company with a meaningful MENA presence, where MS Pharma's CEO previously served. Comparable in specialty/out-licensing business model and MENA distribution intensity.
- Strides Pharma Science: India-based pharmaceutical company focused on generics, specialty, and biosimilars with regulated-market and emerging-market distribution. Comparable in softgel/sterile capabilities and emerging-market partnership-led GTM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks1 record
Key highlights7 records
Customer concentration
MSPharma social profiles
Digital presenceMSPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
MSPharma leadership team
Management profileNumber of profiles
Profiles10 records
MSPharma subsidiaries and ownership
Company hierarchySubsidiaries6 records
MSPharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MSPharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MSPharma
What does MSPharma do?
MS Pharma is a multinational pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines, including biosimilars and biologics, across the MENA region and 70+ countries worldwide. Operating five production facilities in Jordan, Algeria, and Saudi Arabia, the company holds 2,000+ marketing authorizations across 300 INNs spanning cardiovascular, CNS, respiratory, and oncology therapeutic areas. It also serves as a strategic manufacturing and partnership platform for global pharmaceutical companies seeking MENA, EU, and US market access through licensing, supply, and commercialization agreements.
Is MSPharma a public or private company?
MSPharma is a private company. It is classified as family owned and is currently operating.
When was MSPharma founded?
MSPharma was founded in 2011. It employs 1,001 to 5,000 people.
Where is MSPharma based?
MSPharma is headquartered in Amman, Jordan, in the Middle East region.
How does MSPharma make money?
Three revenue lines are on record. Generic and Specialty Pharmaceutical Sales are the primary driver. The others are licensing, Supply, and Commercialization Partnerships and biosimilars and Biologics Portfolio Revenue.
Who are MSPharma's main competitors?
Direct peers on record are Hikma Pharmaceuticals, Tabuk Pharmaceuticals, Julphar (Gulf Pharmaceutical Industries) and SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation). Broad incumbents are Cipla, Aurobindo Pharma and Sandoz (Novartis). EIPICO (Egyptian International Pharmaceutical Industries Co.) is listed as a regional player. Emerging players are Acino International and Strides Pharma Science.
Does MSPharma have an API?
No public API is recorded for MSPharma.
What industry is MSPharma in?
MSPharma's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.